Pulmonary Fibrosis
Admilparant slows lung function decline in IPF, progressive PF
Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC decline in idiopathic and progressive pulmonary fibrosis, according to study results.
Q&A: Online resource aids patients newly diagnosed with pulmonary fibrosis
Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly diagnosed with pulmonary fibrosis feel supported during this time via a new online educational resource.
Q&A: New Pulmonary Fibrosis Foundation chief medical officer to focus on community
Amy Hajari Case, MD, FCCP, has been named chief medical officer of the Pulmonary Fibrosis Foundation, according to a press release.
Antifibrotics increase survival probability in COVID-19, acute respiratory failure
Among patients with COVID-19 and acute respiratory failure, survival at 1 year was more likely if they received nintedanib or pirfenidone antifibrotics, according to results published in BMC Pulmonary Medicine.
Lysophosphatidic acid receptor 1 antagonist slows time to disease progression in IPF
SAN DIEGO — Taking an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks slowed time to disease progression in idiopathic pulmonary fibrosis, according to a presentation at the American Thoracic Society International Conference.
Tool predicts new-onset exertional, resting hypoxemia in patients with fibrotic ILD
A tool that includes age, BMI, two lung function measures and a diagnosis of idiopathic pulmonary fibrosis can predict new-onset exertional and resting hypoxemia in fibrotic interstitial lung disease, according to study results.
Scar tissue patterns may help predict pancreatic cancer outcomes, guide treatment
The organization of cells in scar tissue around pancreatic tumors may help predict survival, according to researchers at Stanford Medicine.
Zinpentraxin alfa comparable to placebo in idiopathic pulmonary fibrosis
Among patients with idiopathic pulmonary fibrosis, lung function decline was comparable between 52-week zinpentraxin alfa treatment and placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.
Race-specific lung function equations misclassify patients with ILD eligible for care
Race-specific vs. race-neutral lung function equations misclassified more patients with pulmonary fibrosis eligible for trials, therapy and transplantation referral, according to results published in Annals of the American Thoracic Society.
High oral microbial diversity linked to poor lung function, mortality risk in IPF
Among patients with idiopathic pulmonary fibrosis, higher microbial diversity in the mouth negatively impacted lung function, according to results published in American Journal of Respiratory and Critical Care Medicine.